B. Riley Securities Maintains Buy on Anika Therapeutics, Raises Price Target to $21

B. Riley Securities analyst Anderson Schock maintains Anika Therapeutics (NASDAQ:ANIK) with a Buy and raises the price target from $18 to $21.